Clarify Pharma PLC Acquisition of Shares (4107H)
24 November 2022 - 6:00PM
UK Regulatory
TIDMPSYC
RNS Number : 4107H
Clarify Pharma PLC
24 November 2022
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014, as retained as part of
the law of England and Wales. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
Press Release
24 November 2022
Clarify Pharma PLC
("Clarify Pharma" or "The Company")
Acquisition of Shares in Atai Life Sciences and Compass
Pathways
Clarify Pharma (AQSE: PSYC), an investment vehicle specialising
in biotech and life sciences companies seeking to prove the safety
and efficacy of psychedelic-based substances, is pleased to
announce it has acquired shares to the value of GBP250,000 in each
of Atai Life Sciences Inc (NASDAQ: ATAI) and Compass Pathways PLC
(NASDAQ: CMPS) as part of its investment strategy.
Atai Life Sciences Inc is a leading biotech company specialised
in psychedelic-based drugs and has prominent backing from venture
capitalists, including entrepreneur and venture capitalist Peter
Thiel. Atai's pipeline features nine programs, four of which are in
the clinical testing stage. The company's lead drug candidate,
RL-007, is being evaluated in a Phase 2 clinical study as a
potential treatment for schizophrenia. Furthermore, Atai's
Perception Neuroscience unit partnered with Otsuka, the Japanese
drugmaker, to develop R-ketamine in treating depression. This
represented the first major collaboration between a
psychedelic-focused biotech and a big pharmaceutical company. Atai
has also acquired and made several strategic investments in
companies in the sector.
Compass Pathways PLC was founded in 2015 to support the research
and development of psilocybin therapy which combines the
pharmacological effects of psilocybin, a psychoactive substance,
with psychological support for the treatment of mental health
challenges. Compass Pathways conducted the largest clinical trial
in the history of psilocybin-assisted therapy with a Phase 2 study
evaluating a synthesised formulation of psilocybin, COMP360, in
treatment-resistant depression. This research is now into
late-stage testing. Compass Pathways has also initiated a Phase 2
study of the therapy in treating post-traumatic stress disorder at
The Institute of Psychiatry, Psychology & Neuroscience at
King's College London.
Jonathan Bixby, Executive Chairman of Clarify Pharma, said: "I
am delighted to announce Clarify Pharma's purchase of shares in two
trailblazing companies which are conducting pioneering research
into psychedelic-assisted therapeutic treatment. Clarify Pharma
continues to pursue new and exciting opportunities in the sector
and is focused on delivering value for shareholders as investors
continue to gain confidence in the regulatory environment for
alternative treatments."
For further information please contact:
Clarify Pharma
Jon Bixby via Tancredi +44 207 887 7633
Executive Chairman
------------------------------
First Sentinel
------------------------------
Corporate Adviser
Brian Stockbridge +44 7876 888 011
------------------------------
Tennyson Securities
------------------------------
Corporate Broker
Peter Krens +44 207 186 9030
------------------------------
Tancredi Intelligent Communication
------------------------------
Media Relations
Catrina Daly
Salamander Davoudi +44 7727 153 868
clarifypharma@tancredigroup.com +44 7957 549 906
------------------------------
About Clarify Pharma PLC:
Listed on the Aquis Stock Exchange in London , Clarify Pharma is
an investment vehicle focusing on investing in biotech and life
sciences companies seeking to prove the safety and efficacy of
psychedelic-based substances. The Company looks to identify
investment opportunities in the life sciences sector within the UK,
Canada and other growing markets, with the objective of generating
long-term capital growth and building investments in an R&D
pipeline of companies which are discovering, developing, or
deploying safe and evidence-based psychedelic inspired medicines
and experiential therapies that alleviate mental health problems
and enhance wellbeing.
The Company's Directors have an established track record,
experience and networks in the psychedelic, cannabinoid and media
industries, to drive value creation.
https://www.clarifypharma.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXEAXFDAAFAFFA
(END) Dow Jones Newswires
November 24, 2022 02:00 ET (07:00 GMT)
Clarify Pharma (AQSE:PSYC)
Historical Stock Chart
From Apr 2024 to May 2024
Clarify Pharma (AQSE:PSYC)
Historical Stock Chart
From May 2023 to May 2024